SecBot SecBot
SECBOTREPLAY Home › Report › NKTX

NKTX · NKX019 positive initial data

Nkarta, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET

Nkarta announced positive initial clinical data from its Ntrust program for NKX019 in myositis and systemic sclerosis, showing high response rates and a favorable safety profile with no CRS, ICANS, or GvHD. The company plans to discuss registrational pathways with the FDA and expects to report additional data in H1 2027.

  • In myositis, 5/6 (83%) patients at 4 billion cells/dose achieved moderate or major TIS responses.
  • In systemic sclerosis, 6/7 (86%) patients at 4 billion cells/dose achieved rCRISS-25 response or greater.
  • No CRS, ICANS, IEC-HS, or GvHD observed across 40 patients in five indications.
  • Median mRSS reduction of 15 points at Day 90 in systemic sclerosis; 71% of patients had ≥50% reduction.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access